{"protocolSection":{"identificationModule":{"nctId":"NCT01800357","orgStudyIdInfo":{"id":"xijing-007"},"organization":{"fullName":"Xijing Hospital","class":"OTHER"},"briefTitle":"Efficacy and Safety of Mildronate for Acute Ischemic Stroke","officialTitle":"Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial"},"statusModule":{"statusVerifiedDate":"2013-01","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-01"},"primaryCompletionDateStruct":{"date":"2014-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2014-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2013-02-25","studyFirstSubmitQcDate":"2013-02-25","studyFirstPostDateStruct":{"date":"2013-02-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-02-25","lastUpdatePostDateStruct":{"date":"2013-02-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xijing Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study seeks to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke","detailedDescription":"a randomized, double-blind, placebo-controlled phase II multicenter trial is conducted to evaluate the efficacy and safety of mildronate injection in patients with acute ischemic stroke. patients will be randomized to receive a 14-day treatment of placebo or mildronate (500mg/5ml/each).Primary end-point is the modified Rankin scale at 3 monthes. Secondary end-point is the NIHSS scores and the Barthel index at 8 days and 15days. The safety end-point is defined as the incidence of adverse events, the change of Samples for routine laboratory tests and vital signs. Analysis is by intention to treat."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["randomized trial","acute ischemic stroke","mildronate"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"mildronate","type":"EXPERIMENTAL","description":"infusion of mildronate","interventionNames":["Drug: infusion of mildronate","Drug: aspirin"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","description":"infusion of placebo mildronate","interventionNames":["Drug: placebo","Drug: aspirin"]}],"interventions":[{"type":"DRUG","name":"infusion of mildronate","description":"infusion of mildronate(500mg) once a day and for 14 days","armGroupLabels":["mildronate"]},{"type":"DRUG","name":"placebo","description":"infusion of plabcebo once a day and for 14 days","armGroupLabels":["placebo"]},{"type":"DRUG","name":"aspirin","description":"infusion of aspirin (100mg) once a day for days","armGroupLabels":["mildronate","placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"the modified Rankin scale","timeFrame":"3 months"}],"secondaryOutcomes":[{"measure":"NIHSS scores","timeFrame":"8 days"},{"measure":"NIHSS scores","timeFrame":"15 days"},{"measure":"the Barthel index","timeFrame":"8 days"},{"measure":"the Barthel index","timeFrame":"15 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n- have a clinical diagnosis of acute ischemic stroke have CT or MRI brain imaging NIHSS scores:5\\~22 on the first stage\n\nExclusion Criteria:\n\n- have other intracranial pathologies are pregnant or nursing have significant drug or alcohol misuse have been in a clinical trial in the past 3 months are unlikely to be available for follow-up have been given thrombolytic therapy or medication forbidden by study protocol have a neurological or psychiatric disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Gang Zhao, MD","role":"CONTACT","phone":"02984775361","email":"zhaogang@fmmu.edu.cn"}],"overallOfficials":[{"name":"Gang Zhao, MD","affiliation":"the Department of Neurology , Xijing Hospital","role":"STUDY_DIRECTOR"},{"name":"Yi Zhu, MD","affiliation":"the Department of Neurology , Xijing Hospital","role":"STUDY_CHAIR"}],"locations":[{"facility":"the Department of Neurology , Xijing Hospital","status":"RECRUITING","city":"Xi'an","state":"Shaanxi","zip":"710032","country":"China","contacts":[{"name":"Gang Zhao, MD","role":"CONTACT","phone":"02984775361","email":"zhaogang@fmmu.edu.cn"},{"name":"Yi Zhu, MD","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Guang Yun Zhang, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.25833,"lon":108.92861}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"C000050147","term":"3-(2,2,2-trimethylhydrazine)propionate"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000000276","term":"Adjuvants, Immunologic"},{"id":"D000007155","term":"Immunologic Factors"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M245820","name":"3-(2,2,2-trimethylhydrazine)propionate","asFound":"GBG","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M3318","name":"Adjuvants, Immunologic","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}